Phase I & II MV-CHIK background studies
Phase I & II Clinical Trials of the MV-CHIK Vaccine
A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus – https://pubmed.ncbi.nih.gov/23742993/
Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates – https://pmc.ncbi.nlm.nih.gov/articles/PMC6667792/
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial – https://pubmed.ncbi.nlm.nih.gov/30409443/
A measles virus-based vaccine induces robust chikungunya virus-specific CD4+ T-cell responses in a phase II clinical trial – https://pubmed.ncbi.nlm.nih.gov/37726181/